Biosensors   

Is Biosensors a good buy?

IMPROVING POTENTIALLY RISKY POLYMERS.  In designing new stents, device makers have been focusing on polymers, thin films that elute healing medication for a month or so. After the drug is gone, the polymer stays behind. The potential for blood clots to form later "is thought to be multifactorial, but in part could be due to inflammation from the polymer," explains Scott Ward , senior vice-president and president of Medtronic's CardioVascular Div. Endeavor's polymer is made of a chemical that the human body normally recognizes as a naturally occurring substance. That could lessen the chance of an inflammatory response, Ward says. Both Abbott and Medtronic are working on developing stents with biodegradable polymers that will dissolve completely over time. That could reduce the risk of blood clots even further.

*** And both Abbott and Medtronic will be caught in BIG's wide patent fencing of "Any limus drug on biodegradable polymer"

8th trump card: Abbott's ABSORB DES (Everolimus drug with biodegradable polymer) 

9th trump card: JNJ's Sirolimus Costar (Sirolimus drug with biodegradable polymer)

10th trump card: MDT's new unknown biodegradable DES ( Zotarolimus drug with biodegradable polymer)

I know for sure BIG's key patent is worth at least US$500m. See all the 3 stent majors are going on biodegradable polymer direction and in breach of BIG's key patent?

 

That means, we still can keep this joker leow, but must be patient leh. I will.

 

TERUMO Initiates World-Wide NOBORI 2 e-Registry April 4, 2008 ? Tokyo, Japan, Leuven, Belgium ? Terumo Corporation, announced today enrolment of the first patient in the NOBORI 2 study designed to further confirm the safety and efficacy of the Nobori® Drug-Eluting Coronary Stent System. ?We are very pleased to enrol the first patient in the NOBORI 2 registry which is expected to generate invaluable long term data about Nobori® stent. The stent was easily delivered and performed well? said Dr. K.E. Hauptmann from Krankenhaus der Barmherzigen Brüder, Trier, Germany, a member of the NOBORI 2 Steering committee. ?Nobori® is not considered as yet another drug eluting stent, but rather as a promising, new treatment option for our patients?, said Dr. M. Wiemer of the Herz- und Diabeteszentrum NRW in Bad Oeynhausen, Germany, the Coordinating investigator for Germany. The NOBORI 2 is the prospective, multi-center, real-life study to validate the safety and effectiveness of Nobori® stent in 3000 patients to be enrolled in more than 20 countries in Europe, Asia, New Zealand and Africa. The primary endpoint is a composite of cardiac death, myocardial infarction and clinically justified target lesion revascularization at 12 months post-procedure. Other major endpoints this study will assess are duration of dual antiplatelet therapy and stent thrombosis in the period up to 5 years. ?NOBORI 2 will allow us to better understand the efficacy and long term safety of the Nobori® stent, in a real life setting? said Dr. G.B. Danzi, of the Ospedale Maggiore Policlinico, Milan, Italy, the Principal Investigator of NOBORI 2. ?Extensive monitoring, electronic data collection independent adverse events adjudication and prespecified subgroups analysis make the NOBORI 2 a distinctive and highly valuable study? added Dr. Danzi. The Nobori® stent with bioresorbable polymer and abluminal coating is a truly new generation drug eluting stent. Nobori?s excellent efficacy and safety have been confirmed through several clinical trials including NOBORI 1 with its two phases, NOBORI CORE and NOBORI Pharmacokinetics study. ?The NOBORI 2 is the key launching event for the Nobori® stent which will further expand our comprehensive product portfolio in interventional cardiology?, said Hideo Arase, President and CEO of Terumo Europe N.V.. ?With combination of Tsunami BMS and Nobori® DES together with other PCI products, Terumo will provide safe and effective options for broad range of patients with coronary artery disease?. About Nobori? stent -------------------------------------------------------------------------------- The Nobori® stent system utilizes Biolimus A9?, an analogue of sirolimus which is expected to reduce tissue proliferation and which is eluted from a bioresorbable polymer, poly-lactic acid. The stent delivery system applies Terumo?s renowned proprietary M Coat® hydrophilic coating for enhances deliverability to challenging lesions. About Terumo -------------------------------------------------------------------------------- Terumo is a global health care company dedicated to research, development, manufacturing and marketing of medical products and equipment, including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular and vascular intervention systems, vascular grafts, peritoneal dialysis, blood glucose monitoring system, medical electronic, and digital thermometers. The main company vision is to contribute to the society through health care using its unique technology which makes medical treatment kinder and gentler. Terumo employs more than 12.000 people and its products are available in over 150 countries world-wide. Biolimus A9? and technology of its elution from bioresorbable polymer (poly-lactic acid) is a proprietary of Biosensors International with whom Terumo, in the year 2003, signed a licensing agreement for the development and marketing of drug eluting stent.

 

Bo pian leow. But ok lah, the market had been pushing very hard to let other blue chips to gain ground, esp Kepcorp, cheong man, tks Mr Lim. He he. May be drop by the coming AGM, see got any good free gifts and foods or not. Cheers.

 

use my stratergy lo..... you cover both risks, ha ha..

 

Yah yah 68 AK shares the same thinking with you, he kelong nevermind but dropping shit. Sigh.

 

These swiss banks better go and take care of their own sub-prime thing than "talk bird" in BIG reports. CS and especially UBS lost so much money in sub-prime, you still dare to place money with them to take care of your "wealth management"??? They cannot even management their own wealth!!! How come they lower TP from $1.30 to $1.20 just because they feel the other 50% China JWMS deal will not go thru? Haven't they heard of "legal due digilence" before entering into a contract??? Before a company buy over another company, the 2 most basic due diligence to perform are financial audit & legal audit. Is JWMS a W.O.F.E. (wholely owned foreign enterprise)? If im not wrong, the first 50% chinaman shareholders hold JWMS shares in a Bermuda company. The lawyers of both parties must have checked that such transactions are allowed by the Chinese government and authorities before start negotiations. To suspect this transaction will not be approved by Chinese authorities and lower TP is quite ridiculous. 

 

BIG better brakes leh, no fun already. Keep it as averaging leow.

 

bro dont like that lar.... still want this guy to drop back to that level.... kenah a few more times....i going to use their product.....

 

to ease your minds, u can use a trick on biosensor... 50% of your holding for the "TOTO strike" - trading halt and kena buyover by someone, then, another 50% of your holding will be "in - and - out ", meaning "contra", like u always buy at 0.68 sell, if it above 80 cents, then, buy again if it comes back low, and sell again..

so, u got win-win situation here you see.. your 50% for long term, will sleep well, it will be 1.00 or maybe 2.00 of course, but then, to add your life more exciting, another 50% just in and out la... sure no problem one, to ease your emotion that, u always wait for it to cheong to 1.00 but always pull back to the original price you buy again... then, u miss so many times of earning...

my stratergy sure works ! cover best and worst case scenario... kekkee

 

 This is amazing. First they say, don't waste money on US but concentrate on Europe and Asia. When BIG announced the China deal, they were negative because of price competition etc in China. Now they say if BIG doesn't get the 100% and the fact that BIG is concentrating on Europe rather than "burning cash for US market entrance' which should boost investor's confidence etc etc...and use words like strong catalyst...YET they TRIM target price from $1.30 to $1.20...... HUH?????? Anyone can explain ???

 

kelong....

 

DJ MARKET TALK:CS Cuts Biosensors Tgt To S$1.20, Keeps Outperform (2008/04/04 08:46AM) 0046 GMT [Dow Jones] STOCK CALL: Credit Suisse trims Biosensors (B20.SG) target price to S$1.20 from S$1.30 after lowering EPS estimates on conservative assumption company will own only 50% of its unlisted China drug-eluting stent subsidiary JW Medical due to uncertainty of China authority''s approval of deal. After company''s presentation at Credit Suisse Asian Investment Conference, says Biosensors appears to be refocusing on Asia, Europe BioMatrix commercialization, rather than burning cash for U.S. market entrance; "We believe this should boost investors'' confidence that the company is on the right path to profitability." Expects October release of large-scale clinical trial results for BioMatrix to offer strong catalyst. Keeps at Outperform. Share closed yesterday down 2.4% at S$0.80. (LES) Contact us in Singapore. 65 64154 150; MarketTalk@dowjones.com (END) Dow Jones Newswires

 

Ha AK no problem lah, being a retiree, but not that old loh 57 only leh. Can drink, sing along etc, hee hee. Looking forward for the unexpected invitation leow. Cheers

 

i think it's the time for this counter to settle down (adjustment) after the long run. hopefully a short rest will gain more energy to "cheong" again.

 

I try arrange it somewhere middle of the month. Its hard to organise one simple lunch gathering as many people are always loaded with so much business and work, esp one Japanese friend of mine always very busy with his jet-setting meetings, lawyer and board meetings, etc. But without his presence we will miss out a lot of fun for the lunch gathering. 

 

Bro.Bengster,

How is your Japan sushi lunch?

May be  arrange next week!!!!!!!!!!!!!

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1

 

There are a few not so good points for BIG as well.

First, I feel they are using stainless steel metal strut which is a rather old technology derived from their BMS s-stent. But since s-stent is already tested and proven and BIG is comfortable with it, so be it as long as it can work. But very competitvely, i feel the metal strut could have been more advanced than using stainless steel.

Second, this company licensed their technology to 3 parties namely Terumo, Xtent and Devax. This effectively means less exclusiveness for BIG's own in-house technology. Licensing will have short term benefits but will reduce takeover valuation. Because BIG's top class DES technology is also being used by 3 licensees, this technology is (if i may put it very crudely) "not so virgin" and lose its exclusiveness. MNCs don't really like the idea of sharing top class technology with others as they want to reap the benefits all for themselves. But BIG is a small company and have to tie up partnerships to exploit their top class DES technology on global platform. The global market is too big for BIG to take on alone. Only true world-class medical device MNCs like MDT, ABT or JNJ can fully exploit top class DES technology within their own corporation and reap all the returns for their own corporation. They have the financial muscle, branding, marketing, sales channel, lobbying power, relationships with hospitals and doctors, etc. all on global platform.  

Thirdly, being a small company with good DES technology will face problems at regulatory approval stage. Lack of lobbying power, kena arm-twist, delay, etc. The regulatory approval stage always are dominated by people who have links with certain large corporations and works like Mafia system. Very hard to crack it. There are many top class drugs and medical devices that never made it pass regulatory stages because of "behind the scene" lobbying by powerful corporations. Its a very dirty business, like mafia business.     

 

Thank YOU so much for the summary...Yes I listened to you but don't have BIG BULLETS to average down much. Happy enough though.Appreciate your sharing ALWAYS.

I just wish the analysts read your postings and if they do, half understand the potential..instead of always concentrating on the fact that there will be losses for the year etc

 

thks Bro bengster for your effort to highlight the whole story up about the on going news.....

Read up every single thing u wrote and really have a feel of what a serious investor need to posses... the info that i might not even want to read and u can digest.. coolz.... ok... support u.. i go now and get 10 lots more... hee...

never in my trading experience that there is such a person focus on just one counter which thinks that it's a great great opportunity and asking people to get it before too late.. I admired his patience though there are still alot of people flame him and laugh at him when the price drop.. haiz.. i have seen alot of that happening during those days when biosensor is like 70 cts range.. haiz.... life's is alway this way..

Ultimately.. it's still YOUR choice whether to take this belief up ok? Time will tell.....

 

cheers to all vested....